कृपया अन्य खोज का प्रयास करें
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ralph R. Weichselbaum | - | 2013 | Member of Scientific Advisory Committee |
Anatoly Dritschilo | 80 | 2012 | Co-Founder, CEO & Chairman of the Board |
Theodore L. Phillips | 91 | 2013 | Chairman of Scientific Advisory Committee |
Milton Brown | 59 | 2012 | Co-Founder & Director |
Christopher H. Senanayake | 66 | 2021 | Independent Director |
J. Martin Brown | - | 2017 | Member of Scientific Advisory Committee |
Steven Richards | 55 | 2012 | Independent Director |
Bette Jacobs | 72 | 2022 | Independent Director |
Joseph Armstrong | - | 2021 | Member of Scientific Advisory Committee |
Alejandro Villagra | - | 2017 | Member of Scientific Advisory Committee |
Joshua M. Schafer | 52 | 2019 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है